The Filing Desk

AdvanSix vs Ingevity

AdvanSix ASIX · Ingevity NGVT · Specialty Chemicals

AdvanSix reported revenue of $1.5 billion in fiscal 2025, 1.3 times Ingevity's $1.2 billion in fiscal 2025. AdvanSix's revenue grew 0.3% in its latest year, and Ingevity's fell 2.7%. Free cash flow was $6 million at AdvanSix and $274 million at Ingevity.

Side by side

AdvanSixIngevity
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$1.5B$1.2B
Revenue growth0.3%−2.7%
Revenue growth a year, last 5 years5.6%−0.8%
Gross margin10.8%39.5%
Operating margin—35.9%
Net margin3.2%−14.3%
Free cash flow$6M$274M
Free cash flow margin0.4%23.4%
Return on capital7.1%24.6%
Net debt to EBITDA−0.1x2.1x
Dividends and buybacks$19M$56M
Change in diluted share count0.3%−0.3%
Last close$15.68$61.72
P/E at the last close—35.7×
Insider trades, last 12 months—sold $1.8 million
Piotroski F-score6 of 96 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
AdvanSixIngevity
Operating margin
Percent of revenue
AdvanSixIngevity
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AdvanSixIngevity

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the AdvanSix and Ingevity pages.